-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The current personalized cancer treatment paradigm is mainly based on the molecular characteristics of cancer cells, such as cancer-causing mutations
CAFs constitute a large part of the tumor microenvironment and are considered to be an important part of the cancer ecosystem
NSCLC breast cancer pancreatic cancer
The lack of a comprehensive understanding of the functional heterogeneity of CAFs hinders the development of more personalized cancer treatments, and previous studies based on various CAF definitions have also produced inconsistent results
Three subtypes of lung cancer fibroblasts define different treatment paradigms
The three subtypes of lung cancer fibroblasts define different treatment paradigmsThe three subtypes of lung cancer fibroblasts define different treatment paradigmsRecently, researchers have established a living biobank of CAFs from living tissues of patients with non-small lung cancer (NSCLC) , including a broad molecular spectrum of CAFs in clinical NSCLC
Researchers have established a living biobank of CAFs from living tissues of patients with non-small lung cancer (NSCLC).
This CAF function classification is related to the patient's clinical response to targeted therapy, and is also related to the tumor immune microenvironment.
Original source:
Original source:Haichuan Hu et al.
Haichuan Hu et al.
Leave a message here